HOME >> BIOLOGY >> NEWS
Early clinical treatment can halt progression of Alzheimer's disease, UCI researchers find

Irvine, Calif. -- UC Irvine neurobiologists have provided the first evidence that early clinical treatment of brain lesions can halt the progression of Alzheimer's disease.

Working on genetically modified mice, the researchers found that using specific antibodies to clear a certain type of brain lesion reversed abnormalities arising from a second type of brain lesion, which halted the progression of the disease. Researchers also found that the earlier the treatment begins, the better the chances of success findings that have similar implications for people, emphasizing the need for better means of early diagnosis and treatment of patients with Alzheimer's disease.

The findings are reported in the Aug. 5 issue of Neuron.

"Current estimates indicate that by the middle of the century, 20 million Americans will suffer from Alzheimer's disease," said Frank LaFerla, associate professor of neurobiology and behavior and head of the research team. "Our results have direct implications for the clinical treatment of this insidious disease."

Alzheimer's is a progressive disease and the most common cause of dementia among the elderly in the United States, affecting 4.5-5 million adults — 10 times more than those affected by Parkinson's disease. The disease is marked by the accumulation of two distinct brain lesions — beta-amyloid plaques and neurofibrillary tangles. Both plaques and tangles accumulate in specific brain regions critical to learning and memory.

It is believed that their accumulation contributes to the destruction of brain cells and the eventual loss of memory. The belief among many neuroscientists that the accumulation of amyloid plaques is the initiating trigger of the disease process constitutes the "amyloid cascade hypothesis" a controversial theory in neuroscience. By showing that the progression of Alzheimer's can be stopped by early treatment of the plaques, the new findings strongly support the h
'"/>

Contact: Iqbal Pittalwala
iqbal@uci.edu
949-824-3969
University of California - Irvine
4-Aug-2004


Page: 1 2 3

Related biology news :

1. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
2. Early detection hope for eye disease
3. Early dexamethasone exposure has long-term neurodevelopment, neuroendocrine effects
4. Early predictor of breast cancer aggressiveness
5. Early treatment confirmed as key to stroke recovery
6. Early identification of kidney disease cost-effective only when directed at high-risk patients
7. Early promise for treatment of Ebola
8. Early treatment can prevent severe vision loss in premature infants
9. Early hominids may have behaved more human than we had thought
10. Early infection and rejection detection
11. Early-life environments shape development of stress behaviors and learning abilities in mice

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/8/2019)... ... May 08, 2019 , ... RG+A, Inc., a leading healthcare ... has agreed to serve as Chief Executive Officer and pharmaceutical leader Dr. Martin ... They will join Chairman and Founder Roger Green to create a three-person executive ...
(Date:5/8/2019)... ... 08, 2019 , ... FISO Technologies proudly presents the innovative ... lead-in fiber of 100 microns. With dimensions smaller than any competitive product, FISO ... world leader in the development of fiber optic sensors & signal conditioners used ...
(Date:5/2/2019)... ... , ... Philadelphia intellectual property law firm Panitch Schwarze ... a registered patent agent, has joined the firm as a new member of ... support and scientific expertise in the pharmaceutical and biotechnical arts and assists in ...
Breaking Biology News(10 mins):
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, Inc., a ... million bench plant expansion to increase production of methylene malonate monomers and oligomers. ... construction of Sirrus’ full-scale production facility, which is scheduled to break ground in ...
(Date:4/9/2019)... ... April 09, 2019 , ... USDM Life Sciences ... life sciences organizations to accelerate innovation and maximize productivity, announces that nearly 100 ... 12 months. , USDM’s Cloud Assurance is a managed subscription service ...
(Date:4/8/2019)... SAN FRANCISCO (PRWEB) , ... April 08, 2019 , ... ... to accredited investors a $15 million preferred equity investment in the privately held pharmaceutical ... dysfunction. Its leading drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced today ... with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility test ... of the $1.7 million already awarded by CARB-X. The additional $1.7M will enable ...
Breaking Biology Technology:
Cached News: